Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 10;20(5):29.
doi: 10.1007/s11926-018-0734-4.

Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis

Silvia Rosina  1 , Giulia Camilla Varnier  1 , Marta Mazzoni  1 , Stefano Lanni  2 , Clara Malattia  1   2 , Angelo Ravelli  3   4
Affiliations
Review

Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis

Silvia Rosina et al. Curr Rheumatol Rep. .

Abstract

Purpose of review: This paper aims to provide a summary of the recent therapeutic advances and the latest research on outcome measures for clinical trials in juvenile dermatomyositis (JDM).

Recent findings: Recent randomized controlled trials (RCTs) have demonstrated the superiority of the combination of prednisone with methotrexate over other conventional therapies and the potential effectiveness of rituximab in refractory cases. A multinational project has led to develop new criteria for the definition of minimal, moderate, and major improvement in future JDM clinical trials. This effort has been paralleled by the establishment of criteria for clinically inactive disease. The validation of the first composite disease activity score for JDM is in progress. The new outcome measures will increase the reliability of assessment of clinical response in JDM clinical trials and foster future multinational RCTs aimed to investigate novel treatment strategies for refractory forms of JDM.

Keywords: Disease remission; Idiopathic inflammatory myopathies; Juvenile dermatomyositis; Outcome measures; Randomized clinical trials.

PubMed Disclaimer

References

    1. Rheumatology (Oxford). 2007 Oct;46(10):1606-11 - PubMed
    1. Rheumatology (Oxford). 2011 Dec;50(12):2237-44 - PubMed
    1. Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53 - PubMed
    1. Autoimmun Rev. 2014 Sep;13(9):883-91 - PubMed
    1. Arthritis Rheum. 2009 May 15;61(5):658-66 - PubMed

MeSH terms

LinkOut - more resources